• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Efficacy and Safety of Spesolimab and Deucravacitinib

Opinion
Video

Mark Lebwohl, MD, and Saakshi Khattri, MD, examine the use of spesolimab in various diseases, including generalized pustular psoriasis (GPP), and comment on the use and safety of deucravacitinib.

This is a video synopsis of a discussion involving Mark Lebwohl, MD, Dean for Clinical Therapeutics and Chairman Emeritus of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai in Manhattan, New York, and Saakshi Khattri, MD, a board-certified dermatologist, rheumatologist, and internist at the same institution.

The panelists delve into the introduction and remarkable efficacy of spesolimab for generalized pustular psoriasis (GPP), emphasizing its life-saving potential. Dr. Khattri recounts a case where a patient experiencing a severe flare of GPP achieved rapid improvement within hours of receiving a single infusion of spesolimab.

They discuss the profound impact of spesolimab's fast-acting nature on patients' quality of life, particularly those with severe manifestations of GPP. Dr. Lebwohl highlights the before-and-after photographs demonstrating the dramatic transformation observed in patients treated with spesolimab.

The conversation shifts to deucravacitinib, another oral option for psoriasis treatment with a distinct mechanism of action. Dr. Khattri explains that deucravacitinib's selective inhibition of TYK2 receptor distinguishes it from other Janus kinase (JAK) inhibitors, resulting in a favorable safety profile without the typical side effects associated with JAK blockade.

Dr. Lebwohl underscores the efficacy of deucravacitinib in palmoplantar psoriasis, a challenging-to-treat subtype, citing promising data indicating improvement in palm and sole lesions. Additionally, they discuss the potential use of deucravacitinib in other neutrophilic diseases like pyoderma gangrenosum and Sweet’s syndrome.

Regarding side effects, Dr. Khattri addresses the common occurrence of oral candidiasis with IL-17 blockade but reassures patients of its manageable nature compared to its efficacy in treating psoriasis.

The panelists conclude that spesolimab and deucravacitinib represent significant advancements in psoriasis treatment, offering rapid and durable responses with favorable safety profiles, thereby improving the management of severe psoriasis and related conditions.

Video synopsis is AI-generated and reviewed by Dermatology Times® editorial staff.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.